News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
This story was originally published on Waste Dive. To receive daily news and insights, subscribe to our free daily Waste Dive newsletter. A Waste Connections subsidiary in June sued Los Angeles County authorities over the 2025 closure of the Chiquita Canyon Landfill, which came …
Sharemaestro market context Trend signal active 52 weeks -9.1%Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. AstraZeneca (LSE:AZN) is reported to be in advanced merger talks with Bristol Myers Squibb. The potential deal could create a combined pharmaceutical company valued at about US$400b. …
Sharemaestro market context Price below Trend Line 52 weeks +14.4%Even if a megamerger fails to materialize, investors stand to benefit from a wave of M&A activity in the biopharma sector. Continue Reading
CNXN Q2 Deep Dive: AI Adoption and Modernization Drive Broad-Based Growth IT solutions provider Connection (NASDAQ:CNXN) beat Wall Street's revenue expectations in Q2 CY2026, with sales up 12.4% year on year to $854 million. Its non-GAAP profit of $1.31 per share was 26% above …
BOSTON and ROLLE, Switzerland, Aug. 4, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH) today announced a new global collaboration to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies with AstraZeneca (LSE/STO/NYSE: AZN).SOPHiA GENETICS Logo This multi-year collaboration agreement will advance …
Sharemaestro market context Price below Trend Line 52 weeks -10.0% · Next-week setup negative 16.9%AstraZeneca shares dropped significantly due to rumors of a potential mega-merger with Bristol Myers Squibb and a failed late-stage trial for its heart disease program, Wainua. Despite these setbacks, an investor is not selling, viewing the decline as a market overreaction rather than a …
Sharemaestro market context Price below Trend Line 52 weeks -1.4%Even if a megamerger fails to materialize, investors stand to benefit from a wave of M&A activity in the biopharma sector. Continue Reading
This page provides a redemption profile for the CNOB5000243 bond issued by ConnectOne Bancorp, Inc., detailing its overview, coupon rate (9.91498%), and maturity date (June 15, 2030). It explains bond redemption as the full repayment of principal and accrued interest, highlighting the importance of …
A recent report indicates that deal talks between AstraZeneca and Bristol-Myers Squibb are still ongoing. Following this news, Bristol-Myers Squibb's shares saw a slight increase, while AstraZeneca's shares experienced a minor decline. This update follows an earlier Financial Times report about potential acquisition discussions.
Morningstar reports on the potential megamerger between Bristol-Myers Squibb and AstraZeneca, noting that such large acquisitions are rare in biopharma. While the deal could combine complementary patent portfolios and pipeline assets, concerns exist regarding integration challenges and regulatory hurdles due to overlapping oncology focuses. …
This article first appeared on GuruFocus. AstraZeneca (NYSE:AZN), a global pharmaceutical company developing cancer, rare-disease and other medicines, plunged approximately 7.7% in Monday's U.S. regular-session trading as investors assessed reported merger discussions with Bristol Myers Squibb (NYSE:BMY), a U.S. biopharmaceutical company. A combination could …
Bristol-Myers Squibb (BMY) shares opened higher on Monday following reports that the U.S. pharma giant held preliminary merger talks with UK rival AstraZeneca (AZN). If finalized, this reported transaction would create the world's largest drugmaker (by revenue) with a market cap approaching $400 billion. …
Thomas C. Baker, Sr. VP, CFO & Treasurer of PC Connection (CNXN), sold common stock worth over $1.6 million on July 31, 2026. The sales involved 19,394 shares at $83.17 and 606 shares at $83.89. Following these transactions, Baker directly holds 36,092 shares.
PC Connection (CNXN) CFO Thomas C. Baker sold a total of 20,000 shares of common stock on July 31, 2026, across two separate open-market transactions. The shares were sold at weighted-average prices of $83.17 and $83.89 per share, totaling approximately $1.66 million. Following these …
World Kinect Corp insider Michael Kasbar has filed a notice to sell 10,000 shares of common stock, valued at $394,146.64, on or after August 3, 2026. These shares are from restricted stock units that vested on March 14, 2025. The filing also notes several …
Fennec Pharmaceuticals' Chief Commercial Officer, Terry L. Evans, acquired 168 Common Shares on July 31, 2026, through the vesting of restricted shares originally awarded in March 2025. This transaction increases his direct holdings to 21,351 Common Shares. The shares were acquired at a price …
Fennec Pharmaceuticals CEO Jeffrey S. Hackman received an award of 1,159 common shares on July 31, 2026, stemming from the release of restrictions on
Fennec Pharmaceuticals' Chief Medical Officer, Pierre Sargis Sayad, acquired 168 common shares on July 31, 2026, as restrictions were released on an award from March 28, 2025. This transaction, valued at $0.00 per share, increased his direct ownership to 21,351 common shares. The acquisition …
Quick Read BMY's existing $2B cost-savings program and discounted forward P/E of ~10 make it an attractive AZN acquisition target, Holz argues. Eli Lilly's $1 trillion market cap dwarfs all pharma rivals, pushing companies like Merck to pursue deals ahead of looming patent cliffs. …
AstraZeneca Plc investors had a clear message for the UK drugmaker on Monday: they don't like the idea of a $400 billion merger with Bristol-Myers Squibb Co. Bloomberg Intelligence's Director of Research, Sam Fazeli joins to discuss. View Comments
The FTSE 100 underperformed European peers on Monday as heavy falls in AstraZeneca outweighed more optimistic noises in the Middle East. The FTSE 100 index closed down 10.35 points, 0.1%, at 10,857.70. The FTSE 250 ended up 249.75 points, 1.0%, at 24,224.77, while the …
Shares in AstraZeneca dropped by nearly 3% at market open after a report that the drugmaker is in talks with oncology rival Bristol Myers Squibb (BMS) regarding a mega-merger deal. According to the Financial Times (FT), which first reported the discussions, a tie-up would …
AstraZeneca stock took a nosedive Monday amid reports it's mulling a megamerger with Bristol Myers Squibb. Continue Reading
Investing.com - AstraZeneca are trading roughly 9% lower on Monday after the Financial Times first reported, followed by Reuters and Bloomberg, that the British drugmaker held preliminary discussions with Bristol Myers Squibb about a combination that would create a nearly $400 billion pharmaceutical giant. …
All three major US stock indexes were up in late-morning trading Monday after President Donald Trump PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already …
AstraZeneca shares plunged Monday on news that the drugmaker was exploring an acquisition of Bristol Meyers Squibb. A deal would create one of the world's biggest drugmakers. Sam Fazeli of Bloomberg Intelligence says a takeover would make no sense. View Comments
European stock markets closed mostly higher in Monday trading as the Stoxx Europe gained 0.4%, Germa PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already …
AstraZeneca completed a direct listing on the New York Stock Exchange back in February, after delisting its American Depositary Receipts from the Nasdaq Credit: Michael Nagle / Bloomberg via Getty Images Key Takeaways Bristol Myers Squibb shares rose Monday following reports of merger talks …
Sharemaestro market context Price below Trend Line 52 weeks +14.4%AstraZeneca stock took a nosedive Monday amid reports it's mulling a mega-merger with Bristol Myers Squibb. Continue Reading
AIM ImmunoTech Inc. Milestone Advances Ampligen® Toward Key Clinical Benefit Readout in December 2026 and Overall Survival Analysis in Mid-2027 OCALA, Fla., Aug. 03, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today announced that the final subject …
AstraZeneca PLC (AZN) shares fell by 8.96% to £115.00 on Monday, underperforming the broader market as the FTSE 100 Index also saw a slight decline. This drop left AstraZeneca's stock 26.90% below its 52-week high achieved in February.
Search by ticker symbol or company name and select a result to open its chart.